RxDoctor Payments Data

Amy Burger, PA

Physician Assistant · Wilmington, NCNPI 1790114114

Payments from drug & device makers

$16,052in general payments, 2019–2025

Across 636 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Dendreon Pharmaceuticals LLC$2K
  • Astellas Pharma US Inc$2K
  • Sumitomo Pharma America, Inc.$1K
  • Johnson & Johnson$917
  • Medtronic$913
  • plus $7K from 40 others

What the payments were for

  • Travel & lodging$1,53310%
  • Food & beverage$14,11388%
  • Education$4063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,052 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$17,161
Medicare patients
122
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron87$69,680
MyrbetriqMirabegron68$54,044
Tamsulosin Hcl348$5,116
Potassium Citrate ErPotassium Citrate21$1,997
Testosterone Cypionate49$1,798
Finasteride105$1,590
Estradiol30$1,403
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst62$1,316
Tadalafil37$805
Methenamine Hippurate16$640
Ciprofloxacin Hcl84$549
Cephalexin17$548
Solifenacin Succinate12$354
Oxybutynin Chloride ErOxybutynin Chloride13$332
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav34$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,457$69,68087 claims
Astellas Pharma US IncMyrbetriq$1,625$54,04468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →